Ascendis Enters into Collaboration with Teijin Limited to Develop & Commercialize TransCon hGH, TransCon PTH, & TransCon CNP in Japan
Shots:
- Ascendis Pharma has signed an exclusive license deal with Teijin for advancing TransCon hGH, TransCon PTH, & TransCon CNP in Japan, focusing on rare endocrinology diseases
- Ascendis Pharma will receive an up front payment of $70M, along with development & regulatory milestones of ~$175M. The agreement also includes transfer pricing, commercial milestones, & royalties on net sales in Japan, ranging up to the mid-20s percent, varying by product
- The collaboration leverages Teijin Pharma's expertise in navigating regulatory approval & commercialization of rare endocrinology diseases products in Japan. Furthermore, Ascendis utilizes its innovative TransCon technology to develop unique product candidates, enhancing its pharmaceutical portfolio
Ref: Globe Newswire | Image: Ascendis
Related News:- Ascendis Pharma’s TransCon hGH Receives EC’s Approval for Pediatric Growth Hormone Deficiency
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
